This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Autologous therapies are characterized as a circular supplychain; the patient’s own sample starts the supplychain, and it is then subjected to ex-vivo modifications with the resulting therapy administered back to that same patient. CGT trials operate with much lower volumes of manufactured final product.
As the clinical trials industry adapts to the rising demand, it must also tackle important challenges concerning the way advanced medicines like cell and gene therapies are handled. Cell and gene therapies are not your typical clinicalsupplychain. The risk of mistakes caused by improper planning are enormous.
Supplychain uncertainty is a challenge every clinicalsupplychain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supplychain.
. “Surgence is not a competitive product but a holistic solution. Many third-party supplychain solutions exist in the market, but none have the full suite offerings available in Surgence,” said Cody Fisher, Concordance EVP and strategic advisor in the company’s news release.
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinicalsupplychain to help meet patient requirements, improve supplychain efficiency and accelerate speed to market.
The benefits of developing a patient-centric clinicalsupplychain.
Find out solutions to mitigate the impact from clinicalsupplychain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.
XTALKS WEBINAR: Fostering Patient-Centricity: ClinicalSupplyChain Strategies and Sourcing Solutions Live and On-Demand: Thursday, July 20, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how to review clinical trial trends and supply strategies that impact the patient experience.
BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production. BioNTech has agreed to buy a Novartis manufacturing facility in Marbury, Germany, to expand its Covid-19 vaccine production capacity by up to 750 million doses per year, or more than 60 million doses per month, once fully operational.
The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinicalsupplychain efforts.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. In addition, the time-savings offered by this facility in the clinicalsupplychain are considerable.
When war broke out in Ukraine in early 2022, many clinical trial patients had to flee the country or relocate, presenting considerable disruption to existing clinical trials and risking data collection on medical products. The situation has tested business continuity plans to their limits. But it doesn’t end there. “We’re
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content